Medizinische Universität Innsbruck - Austria
AUTHOR PROILE
Scopus
EARLY ACADEMIC PURSUITS:
Isabel Heidegger commenced her academic journey with a strong foundation in the field of medicine. She pursued her early education with a focus on urology, setting the stage for her future contributions to the medical community.
PROFESSIONAL ENDEAVORS:
Isabel Heidegger's professional journey has been marked by significant achievements. Joining the Department of Urology at the Medical University Innsbruck in 1984, she steadily progressed in her career. Currently holding the distinguished position of Professor of Translational Prostate Cancer Therapy and Deputy Director of the Department of Urology, her leadership is evident in both clinical and research aspects.
Heidegger has made substantial contributions to the field of oncology and precision medicine, with a primary focus on translational prostate cancer therapy. Her work encompasses both basic-translational and clinical science. Her dedication to prostate cancer research extends to conservative and surgical treatment modalities.
IMPACT AND INFLUENCE:
As a physician-scientist specializing in prostate cancer, Heidegger's impact reverberates through her extensive research and clinical endeavors. Her commitment to advancing knowledge and improving patient outcomes has positioned her as a key influencer in the domain of urology.
ACADEMIC CITES:
Isabel Heidegger's work has garnered recognition in academic circles, evident in her citations and contributions to scholarly publications. Her research findings and clinical insights have contributed to the academic discourse in urology and prostate cancer treatment.
LEGACY AND FUTURE CONTRIBUTIONS:
Heidegger's legacy is shaped by her tireless pursuit of excellence in prostate cancer research and therapy. Her ongoing contributions lay the groundwork for future advancements in urology. The impact of her work is poised to endure, leaving a lasting legacy in the realm of translational medicine and prostate cancer treatment.
NOTABLE PUBLICATION
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.2023
Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response.2022
-